Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03591874 · ClinicalTrials.gov registry record · Phase 3
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
A Phase 3 study, sponsored by Ocugen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT03591874 is a Phase 3 study that was terminated before completion, run by Ocugen. The registered enrollment target is 59 participants.
The verdict
NCT03591874, a Phase 3 study, was terminated before completion, sponsored by Ocugen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).
Interventions
- DRUG Placebos
- DRUG Brimonidine Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-12-23 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03591874
The ClinicalTrials.gov registry entry for NCT03591874 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03591874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03591874 about?
NCT03591874 is a clinical study titled "Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease". This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).
What is the current status of trial NCT03591874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2018-12-23. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT03591874?
The interventions under investigation include: Placebos (DRUG), Brimonidine Tartrate (DRUG).
Who is sponsoring clinical trial NCT03591874?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.